title: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk.
abstract: OBJECTIVE
  We examine the relationship of nonsteroidal anti-inflammatory drugs and finasteride on the risk of prostate cancer.
  
  
  METHODS
  Participants in this case control study using a prospective collection of data were drawn from consecutive patients who underwent prostate biopsy at 12 different departments of urology from January 1999 to June 2000. Medication use was assessed by self-questionnaire as well as questions about dietary and lifestyle factors that might be relevant for prostate cancer risk.
  
  
  RESULTS
  The study included 639 patients with prostate cancer and 659 cancer-free controls. Univariate analysis showed no significant impact of aspirin and finasteride on prostate cancer risk while the nonaspirin nonsteroidal anti-inflammatory drug users had a lower risk (OR 0.80, 95% CI 0.64-0.99). After adjusting for potential confounders, the protective effect of nonaspirin nonsteroidal anti-inflammatory drugs was no longer significant (OR, 0.84, 95% CI 0.66-1.07), while finasteride showed a significant protective effect (OR 0.58, 95% CI 0.37-0.92).
  
  
  CONCLUSIONS
  The results suggest that finasteride could have a chemopreventive role in prostate cancer. While aspirin did not show any impact on prostate cancer risk, the role of nonaspirin nonsteroidal anti-inflammatory drugs warrants further studies.
authors.affiliation: University Hospital of Poitiers, France.
authors.forename: J
authors.initials: J
authors.lastname: Irani
authors.forename: V
authors.initials: V
authors.lastname: Ravery
authors.forename: J L
authors.initials: JL
authors.lastname: Pariente
authors.forename: E
authors.initials: E
authors.lastname: Chartier-Kastler
authors.forename: E
authors.initials: E
authors.lastname: Lechevallier
authors.forename: M
authors.initials: M
authors.lastname: Soulie
authors.forename: D
authors.initials: D
authors.lastname: Chautard
authors.forename: P
authors.initials: P
authors.lastname: Coloby
authors.forename: E
authors.initials: E
authors.lastname: Fontaine
authors.forename: F
authors.initials: F
authors.lastname: Bladou
authors.forename: F
authors.initials: F
authors.lastname: Desgrandchamps
authors.forename: O
authors.initials: O
authors.lastname: Haillot
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D001706:Biopsy; D016022:Case-Control Studies; D018120:Finasteride / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D012306:Risk
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018120:Finasteride; D001241:Aspirin